Dublin, Jan. 18, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/53xptt/world_market_for) has announced the addition of the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)" report to their offering.
The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It's a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.
The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.
The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.
The following companies are profiled in this report:
- Allergan Inc.
- Allergan Inamed Corporation
- Barrier Therapeutics, Inc
- Bayer AG
- PharmaDerm Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Collagenex (now Galderma) Pharmaceuticals
- Galderma S.A.
- Genentech, Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
- Medicis Pharmaceutical Corporation
- Merck & Company, Inc.
- Mylan Pharmaceuticals, Inc,
- Novartis Pharmaceuticals Corporation
- Nycomed Inc.
- Pfizer, Inc.
- Q-Med AB
- Roche Group (F. Hoffmann-La Roche Ltd.)
- Schering (now Merck)-Plough Corporation
- Sinclair Pharma Plc.
- SkinMedica
- Stiefel Laboratories, Inc.
- Valeant Pharmaceuticals, Inc.
Key Topics Covered:
Chapter One: Executive Summary
Chapter Two: Introduction
Chapter Three: Issues And Trends
Chapter Four: Prescription Antiacne And Rosacea Drugs
Chapter Five: Prescription Antiaging And Photodamage Drugs
Chapter Six: Prescription Dermatitis And Seborrhea Drugs
Chapter Seven: Prescription Antifungal Drugs
Chapter Eight: Prescription Hair Loss And Hair Removal Drugs
Chapter Nine: Prescription Hyperpigmentation/Melasma And Depigmenting Drugs
Chapter Ten: Prescription Psoriasis Drugs
Chapter Eleven: Prescription Skin Cancer Drugs
Chapter Twelve: Miscellaneous Skin Disorder Drugs
Chapter Thirteen: World Market Summary
Chapter Fourteen: Corporate Profiles
For more information visit http://www.researchandmarkets.com/research/53xptt/world_market_for
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals, Skin Cancer


Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 



